DRREDDY

Dec 31 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR. REDDY'S LABORATORIES SA RECEIVES COMPLETE RESPONSE LETTER FROM USFDA

• LETTER REFERS TO INSPECTION OBSERVATIONS AT ALVOTECH FACILITY

• COMPLETE RESPONSE LETTER FOR BLA FOR AVT03 BIOSIMILAR TO PROLIA & XGEVA

Source text: ID:nNSEbhHnJd

Further company coverage: REDY.NS

(([email protected];))

Dec 8 (Reuters) - Immutep Ltd IMM.AX:

• IMMUTEP ENTERS INTO STRATEGIC COLLABORATION WITH DR. REDDY'S

• IMMUTEP TO RECEIVE UPFRONT PAYMENT OF USD 20 MILLION

• ELIGIBLE TO RECEIVE POTENTIAL REGULATORY DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS OF UP TO USD 349.5 MILLION

Further company coverage: IMM.AX

(([email protected];))

Updates to add comment from Novo Nordisk in para 5, 6, 7

By Rishika Sadam

HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's most populous nation.

India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers vying for a share of the fast-growing weight-loss treatment market, which analysts expect to reach $150 billion annually by the end of the decade.

Ozempic, a once-weekly injectable approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight loss due to its appetite-suppressing effects. Novo's Wegovy, which like Ozempic is semaglutide, is approved for weight loss.

"Novo wants Ozempic in the market before generics bring out cheaper versions," one of the sources said, adding the launch could happen within the next three to four weeks.

Novo, which in September said it secured Indian regulatory approval to import and sell Ozempic, on Thursday said it hoped to launch the drug as early as possible, but did not give further details on an updated timeline or the drug's pricing.

"We understand that India is a price sensitive market and hence we are working hard towards pricing (Ozempic) that is market competitive," Novo Nordisk India Managing Director Vikrant Shrotriya told Reuters in an email.

Ozempic arrival in India will complete Novo's semaglutide portfolio offering treatment for diabetes and obesity in the country, he said.

The move comes as Wegovy faces stiff competition from U.S. rival Eli Lilly LLY.N, whose Mounjaro, which is approved for diabetes and weight loss, became India's top-selling drug by value in October, according to Pharmarack data.

LILLY HOLD LEAD, GENERICS ON THE HORIZON

Lilly sold 262,000 doses of Mounjaro in October, compared with 26,000 doses of Novo's Wegovy, which entered the market in June.

Last month, Novo cut Wegovy's price in India by up to 37% ahead of the March 2026 expiration of its patent on semaglutide, which will open the door to cheaper generics.

India's generic drugmakers including Sun Pharma SUN.NS, Cipla CIPL.NS, Dr Reddy's REDY.NS and Lupin LUPN.NS have been developing their own versions of semaglutide to get in on the weight-loss windfall.

Novo already has a strong foothold in India's diabetes market through its Rybelsus semaglutide tablets and other products, Systematix Institutional Equities analyst Vishal Manchanda said, adding that Novo will be better poised to push Ozempic because of its strong brand reputation in the diabetes therapy area.

"There is a possibility that Ozempic could be prescribed for those suffering with infertility, sleep apnea and looking to shed some weight," Manchanda said.

Ozempic, Wegovy and Mounjaro belong to a class of drugs known as GLP-1 agonists originally developed for diabetes, but which mimic a hormone that also slows digestion and helps people feel full longer.

(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Bill Berkrot)

(([email protected];))

By Rishika Sadam

HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's most populous nation.

India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers vying for a share of the fast-growing weight-loss treatment market, which analysts expect to reach $150 billion annually by the end of the decade.

Ozempic, a once-weekly injectable approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight loss due to its appetite-suppressing effects. Novo's Wegovy, which like Ozempic is semaglutide, is approved for weight loss.

"Novo wants Ozempic in the market before generics bring out cheaper versions," one of the sources said, adding the launch could happen within the next three to four weeks.

Novo in September said it secured Indian regulatory approval to import and sell Ozempic and hoped to launch as soon as possible, but did not immediately respond to requests for comment on an updated timeline or the drug's pricing.

The move comes as Wegovy faces stiff competition from U.S. rival Eli Lilly LLY.N, whose Mounjaro, which is approved for diabetes and weight loss, became India's top-selling drug by value in October, according to Pharmarack data.

LILLY HOLD LEAD, GENERICS ON THE HORIZON

Lilly sold 262,000 doses of Mounjaro in October, compared with 26,000 doses of Novo's Wegovy, which entered the market in June.

Last month, Novo cut Wegovy's price in India by up to 37% ahead of the March 2026 expiration of its patent on semaglutide, which will open the door to cheaper generics.

India's generic drugmakers including Sun Pharma SUN.NS, Cipla CIPL.NS, Dr Reddy's REDY.NS and Lupin LUPN.NS have been developing their own versions of semaglutide to get in on the weight-loss windfall.

Novo already has a strong foothold in India's diabetes market through its Rybelsus semaglutide tablets and other products, Systematix Institutional Equities analyst Vishal Manchanda said, adding that Novo will be better poised to push Ozempic because of its strong brand reputation in the diabetes therapy area.

"There is a possibility that Ozempic could be prescribed for those suffering with infertility, sleep apnea and looking to shed some weight," Manchanda said.

Ozempic, Wegovy and Mounjaro belong to a class of drugs known as GLP-1 agonists originally developed for diabetes, but which mimic a hormone that also slows digestion and helps people feel full longer.

(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Bill Berkrot)

(([email protected];))

Nov 27 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX:

• SIGNS DISTRIBUTION AGREEMENT WITH DR. REDDY'S LABORATORIES

• AGREEMENT TO SUPPLY CHEMOTHERAPY MEDICINE CAPECITABINE INTO AUSTRALIAN MARKET

Further company coverage: 1AI.AX

(([email protected];))

Changes dateline, adds CSL in last paragraph

Nov 18 (Reuters) - Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.

It will also invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

CSL CSL.AX

Australia's CSL said it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the North American country over the next five years.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh and Sneha S K in Bengaluru; Editing by Devika Syamnath, Leroy Leo, Vijay Kishore, Sahal Muhammed and Maju Samuel)

(([email protected];))

Oct 24 (Reuters) -

• DR REDDY'S EXEC: NOT LOOKING FOR PARTNERSHIP WITH ELI LILLY FOR LAUNCHING TIRZEPATIDE IN INDIA

Source text: [ID:]

Further company coverage: LLY.N

(([email protected];))

Updates with Amgen's investment plan

Sept 26 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.

However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Pfizer PFE.N

Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)

(([email protected];))

By Rishika Sadam and Jennifer Rigby

Sept 24 (Reuters) - Indian drugmakers Dr Reddy's Laboratories REDY.NS and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly effective HIV prevention drug for roughly $40 per year beginning in 2027.

Lenacapavir, developed by Gilead Sciences GILD.O and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly injection that was nearly 100% effective at preventing HIV in large trials.

Some AIDS experts, including activists and doctors, say it could help control the 44-year-long epidemic that still infects 1.3 million people a year, and which the World Health Organization estimates has killed 44 million.

ENABLING BROADER ACCESS

The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated U.S. price of around $28,000 a year for branded Yeztugo.

Unitaid, a WHO-hosted global health agency that works on bringing new tools and medicines to countries more cheaply, is providing technical and financial support to Dr Reddy's for the low-cost effort, alongside the Clinton Health Access Initiative and South Africa's Wits Reproductive Health and HIV Institute (Wits RHI), part of University of the Witwatersrand.

The Gates Foundation is working with Hetero.

"Generic manufacture of lenacapavir is essential to ensure this breakthrough HIV prevention option is not limited to a privileged few," said Professor Saiqa Mullick, director of implementation science at Wits RHI.

The generic version with its low price point could be a preferred choice by millions affected in low-income countries, Mullick said.

The two manufacturers are among six Gilead granted royalty-free licenses to last year, to produce and sell the drug in 120 low- and lower-middle income countries with the highest global HIV disease burden by 2027, subject to approvals.

"The ($40) price that we have negotiated... brings the product in parity with the cost of the oral PrEP," Carmen Perez Casas, Unitaid's strategic lead for HIV, told Reuters, using the short phrase for pre-exposure prophylaxis, or preventive, drugs.

Injections at six-month intervals could benefit people for whom stigma, logistics, and other barriers make it difficult to take a pill every day, she added.

CHEAP GENERICS NEEDED FOR LONG-TERM DEMAND

U.S. biotech Gilead has faced criticism from patient advocacy groups and activists for not including upper-middle- income countries such as those in Latin America in the generics agreement.

"We are supporting organizations and countries to reflect on how we could overcome those access barriers (in excluded nations)," Casas said, noting that some countries, including Brazil, took part in trials of the medication but could not access the generics as the agreement with Gilead stands.

Gilead is already working with the Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government to get doses of its branded drug at a reduced price to 2 million people starting this year while generics ramp up production.

But experts estimate that long-term demand is likely to be closer to 10 million people or more, highlighting the need for cheaper generics at scale.

"The availability of generics at an affordable price... will magnify the impact of this game-changing innovation," Peter Sands, chief executive of the Global Fund, told Reuters.

($1 = 88.6930 Indian rupees)

(Reporting by Rishika Sadam in Bengaluru and Jennifer Rigby in New York; Editing by Bill Berkrot)

(([email protected];))

Sept 22 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - RECEIVES POSITIVE CHMP OPINION FOR AVT03 BIOSIMILAR

• DR REDDY'S LABORATORIES LTD - HAS EXCLUSIVE U.S. RIGHTS FOR AVT03

Source text: ID:nBSE9Yk6hw

Further company coverage: REDY.NS

(([email protected];))

Updates with GSK's investment plan

Sept 17 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.

However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

Pfizer PFE.N

Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)

(([email protected];))

Sept 16 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• LAUNCHES NOVEL MOLECULE 'TEGOPRAZAN' IN INDIA

Further company coverage: REDY.NS

(([email protected];;))

Sept 3 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%.

But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Eli Lilly LLY.N

The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

Pfizer PFE.N

Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)

(([email protected];))

Updates with afternoon levels

By Ragini Mathur, Johann M Cherian and Sukriti Gupta

Aug 6 (Reuters) - Chile's peso declined the most among Latin American currencies on Wednesday, after the local central bank unveiled plans to boost international reserves, while investors were also scrutinizing U.S. tariffs on India and Brazil.

In a move that surprised investors, U.S. President Donald Trump unveiled an additional tariff on Indian goods , set to take effect 21 days after August 7. The new tariff will push duties on some Indian exports as high as 50% – among the steepest imposed on any U.S. trading partner.

Trump cited New Delhi's continued purchases of Russian oil as the reason for the sharply increased tariff rate.

Indian markets closed before the news, but a U.S.-listed iShares India ETF INDA.N slipped 0.3% to a three-month low. Depository receipts of Dr Reddy's Laboratories RDY.N REDY.NS lost 2.5% and those of Wipro WIT.N WIPR.NS and Infosys INFY.N INFY.NS dipped 1.5% and 0.9%, respectively.

On the currency front, the 1-month rupee forward INR1MNDFOR= was last flat against the dollar.

"While markets have already started pricing in the risk of a sharp tariff hike, a near-term knee-jerk reaction is inevitable — unless there's swift clarity or a breakthrough in negotiations," said Mayuresh Joshi, head of India equity research at William O'Neil.

"India's crude oil imports have remained diversified ... Russia is just one slice of our broader crude basket."

In Latin America, Brazil's real BRL= firmed 0.8% against a weaker dollar and touched a near one-month high and stocks .BVSP gained 1.1% to hit a two-week high as 50% U.S. tariffs on the country's exports took effect.

The U.S. enjoys a trade surplus with Brazil and top export items from the South American country were exempted from the duties last week. The BRICS group of countries has come under greater scrutiny in recent weeks as Trump accused them of pursuing "anti-American policies".

Brazil's President Luiz Inacio Lula da Silva told Reuters in an interview that he saw no room for direct talks with U.S. President Donald Trump, which he believes would turn into a "humiliation" for him.

Meanwhile, Chile's currency fell 0.7% after the country's central bank announced a three-year plan to boost international reserves by $18.5 billion, aiming to strengthen its holdings and reduce dependence on foreign credit lines.

Citigroup moved to "underweight" on the Chilean peso in its EM Bond Portfolio following the reserves program announcement.

Mexico's peso MXN= firmed 0.7% ahead of an interest rate decision by the domestic central bank on Thursday.

Elsewhere, Trump said his special envoy Steve Witkoff had made "great progress" in his meeting with Russian President Vladimir Putin, two days before a deadline set to impose new sanctions if no moves were made to end the conflict with Ukraine.

Crude prices slid to an eight-week low on the sanction uncertainty. The rouble RUB= had closed lower earlier on Wednesday, while international bonds in Ukraine rose broadly.

Key Latin American stock indexes and currencies:

(Reporting by Sukriti Gupta, Purvi Agarwal, Ragini Mathur and Johann M Cherian in Bengaluru; Editing by Richard Chang and Mohammed Safi Shamsi)

(([email protected]))

July 25 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - INVESTS 5.65 BILLION RUPEES FOR 45.19% STAKE IN DRL RUSSIA

Source text: ID:nBSEfgZDN

Further company coverage: REDY.NS

(([email protected];;))

• Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on July 23 for the period ending June 30 2025

• The Hyderabad Telangana-based company is expected to report a 14.6% increase in revenue to ₹88.234 billion from ₹76.96 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹18.00 per share.

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $16.37, about 11.5% above its last closing price of $14.48

This summary was machine generated July 21 at 11:01 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])

July 18 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - USFDA COMPLETES INSPECTION AT DR. REDDY'S SRIKAKULAM FACILITY

• DR REDDY'S LABORATORIES LTD - ISSUED FORM 483 WITH 7 OBSERVATIONS BY USFDA

Source text: ID:nBSE6WH7dN

Further company coverage: REDY.NS

(([email protected];))